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Background: Exploration of immunomodulatory antileishmanials of plant origin is now being strongly recommended
to overcome the immune suppression evident during visceral leishmaniasis (VL) and high cost and toxicity associated
with conventional chemotherapeutics. In accordance, we assessed the in vitro and in vivo antileishmanial and
immunomodulatory potential of ethanolic fractions of Azadirachta indica leaves (ALE) and seeds (ASE).
Methods: A. indica fractions were prepared by sequential extraction of the powdered plant parts in hexane, ethanol
and water. Erythrosin B staining was employed to appraise the anti-promastigote potential of ALE and ASE. Cytostatic
or cytocidal mode of action was ascertained and alterations in parasite morphology were depicted under oil immersion
light microscopy. Study of apoptotic correlates was performed to deduce the mechanism of induced cell death and
anti-amastigote potential was assessed in Leishmania parasitized RAW 264.7 macrophages. In vivo antileishmanial
effectiveness was evaluated in L. donovani infected BALB/c mice, accompanied by investigation of immunomodulatory
potential of ALE and ASE. Adverse toxicity of the bioactive fractions against RAW macrophages was studied by MTT
assay. In vivo side effects on the liver and kidney functions were also determined. Plant secondary metabolites present
in ALE and ASE were analysed by Gas chromatography–mass spectrometry (GC-MS).
Results: ALE and ASE (500 μg ml−1) exhibited leishmanicidal activity in a time- and dose-dependent manner (IC50 34
and 77.66 μg ml−1, respectively) with alterations in promastigote morphology and induction of apoptosis. ALE and
ASE exerted appreciable anti-amastigote potency (IC50 17.66 and 24.66 μg ml−1, respectively) that was coupled with
profound in vivo therapeutic efficacy (87.76% and 85.54% protection in liver and 85.55% and 83.62% in spleen,
respectively). ALE exhibited minimal toxicity with selectivity index of 26.10 whereas ASE was observed to be non-toxic.
The bioactive fractions revealed no hepato- and nephro-toxicity. ALE and ASE potentiated Th1-biased cell-mediated
immunity along with upregulation of INF-γ, TNF-α and IL-2 and decline in IL-4 and IL-10 levels. GC-MS analysis revealed
several compounds that may have contributed to the observed antileishmanial effect.
Conclusion: Dual antileishmanial and immunostimulatory efficacy exhibited by the bioactive fractions merits their use
alone or as adjunct therapy for VL.
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Leishmaniasis is a complex poverty associated vector-
borne illness that presents a distinct array of clinical
patterns and includes visceral leishmaniasis (VL), which is po-
tentially fatal, if left untreated. VL, also known as Kala-azar
is attributable to parasites of L. donovani complex and is
characterized by fever (usually with rigor and chills), cach-
exia, anaemia, hepato- and spleno-megaly, pancytopenia,
polyclonal hypergammaglobulinemia and hyperpigmenta-
tion resulting in characteristic darkening of skin. More
than 90% of disease burden (60,000 deaths and incidence
of 500,000 cases per annum) is borne by India, Bangladesh,
Nepal, Sudan, Ethopia, and Brazil. Around 200 million
people living in 109 districts in India, Bangladesh and Nepal
are at constant risk of developing visceral infection and
relapse after complete cure in the form of post kala-azar
dermal leishmaniasis further adds to the complications.
The escalating drug resistance exhibited by the Leishmania
parasites had already led to withdrawal of the first line
drugs from therapeutic regimen in India. By evolving as a
co-infection with HIV, VL has expanded its niche to other
non-endemic countries, and has managed to seek immedi-
ate attention towards its timely control [1,2]. In case of
parasitic diseases, recovery is often associated with direct
parasite killing in synergy with activation of the depressed
immune system [3]. Progressive VL is also characterized by
profound suppression of the immune system, which re-
sults in acute parasitic load. Thus, drugs that can simul-
taneously cause parasite death as well as activation of cell
mediated immunity (CMI) can surely benefit the crippled
chemotherapy against leishmaniasis. Use of medicinal
plants as antidotes against parasitic infections is well-
documented and herbal preparations that possess dual
anti-parasitic and immunomodulatory properties have
been pivotal to many classical systems of medicine. A
huge number of plants with immunomodulatory potential
have been explored for antileishmanial activity and have
yielded promising results [4,5].
Azadirachta indica (neem) belonging to the family
Meliaceae has become a focus of modern medicine as it
has been used since ages in Ayurveda, Unani and Homeo-
pathic systems of medicine. Every part of the neem tree
possesses a wide array of biologically active compounds
with medicinal potency. A. indica oil and the bark and leaf
extracts have therapeutic efficacy against leprosy, intes-
tinal helminthiasis and respiratory disorders in children.
Leaf and seed extracts possess immunomodulatory, in-
secticidal, antiseptic, antitumor, anticancer, antiviral, anti-
fungal and antiprotozoal properties ([6] and references
therein). Chloroform extracts of A. indica leaves distinctly
restrained growth of Trypanosoma cruzi epimastigotes
with ultrastructural alterations indicated by vacuolization,
organelle disintegration and disruptions in cell division
[7]. A. indica extracts have also been demonstrated to beantileishmanial against new world species both, in vitro
[8-10] and in vivo [11]. Aqueous extracts of A. indica
whole plant [12] and of different parts [13] have been earl-
ier reported to be leishmanicidal in vivo and in vitro
against L. donovani promastigotes (Dd8 and other strains)
but none of the studies elucidated the detailed mechanism
of action of these extracts. Thus, these studies provoked
us to formulate different fractions of A. indica, evaluate
their antileishmanial potential and illustrate the mechan-
ism of induced cell death as well as to identify the plant
secondary metabolites, which could be responsible for the
observed leishmanicidal potency.
Methods
M199 medium, Roswell Park Memorial Institute (RPMI)
1640 medium, penicillin G sodium salt, streptomycin
sulphate, propidium iodide (PI), glutamine and pentamidine
were purchased from Sigma-Aldrich, fetal bovine serum
(FBS) from Biowest, dimethylsulfoxide (DMSO) from SRL,
4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES)
from Himedia, isopropanol and methanol from Merck.
Annexin V–FLUOS staining kit and ApoDirect kits were
procured from Roche Inc., Switzerland. All the antibodies
and their isotype controls were procured from BD Bio-
sciences. All the other chemicals were obtained from
Sigma-Aldrich unless stated otherwise.
Parasite culture and maintenance
L. donovani infection (MHOM/IN/83/AG83) was main-
tained by passage in BALB/c mice. Medium 199 (M199),
pH 7.4 supplemented with penicillin G sodium (100 U ml−1),
streptomycin sulfate (100 μg ml−1), HEPES (25 mM) and
10% heat-inactivated FBS (complete M199) was used to
culture the promastigotes. Subculturing was done at regu-
lar intervals (72–96 h) after adjusting the inoculum dens-
ity to 2 × 106 cells ml−1 at 22°C [14].
Macrophage culture and maintenance
Murine macrophage-like adherent cell line RAW 264.7
was maintained in RPMI 1640 medium in a humidified at-
mosphere and 5% CO2 at 37°C. The medium was supple-
mented with 100 μg ml−1 streptomycin sulfate, 100 U ml−1
penicillin G-sodium, 0.2% sodium bicarbonate, 25 mM
HEPES and 10% FBS. The cell line was sub-cultured every
3 days in the same medium [15].
Animals
For in vivo experiments, a prior consent was obtained
from the Jamia Hamdard Animal Ethics Committee
(JHAEC) for the research protocol (Ethical approval
judgement number 499). JHAEC is registered under the
Committee for the purpose of control and supervision of
experiments on animals (CPCSEA). In present study, fe-
male BALB/c mice at 6–8 weeks of age and weighing
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ally placed in standard size polycarbonate cages with
controlled conditions of temperature (23 ± 1°C), humidity
(55 ± 10%) and 12:12 h of light and dark cycles. The animals
were fed with a standard pellet diet (Ashirwad Industries,
Chandigarh, India) and filtered water ad libitum in the
Central Animal House of Jamia Hamdard in accordance
with internationally established principles.
Preparation of plant fractions
A. indica bark, leaves and seeds were obtained from the
Herbal Garden of Jamia Hamdard. The plant samples
were thoroughly washed with distilled water, shade
dried, ground to powder form and sequentially extracted
in hexane, ethanol and water by percolation [16]. The
respective fractions were pooled and concentrated to
dryness under vacuum by rotary evaporation at 35°C.
The dried solvent and lyophilized aqueous fractions were
stored at −20°C until used for bioassay.
Evaluation of anti-promastigote potential of A. indica fractions
Anti-promastigote activity was appraised by incubating
L. donovani promastigotes with different A. indica frac-
tions followed by enumeration of the viable cells after
erythrosin B (0.2%, 1:1) staining. Briefly, stationary phase
promastigotes (2 × 106 cells ml−1) were incubated at 22°C
with or without the test fractions (500 μg ml−1) or pent-
amidine (a known antileishmanial drug, serving as positive
control) at equivalent concentration. DMSO (0.5%), which
was used to solubilize the A. indica fractions, was also
assayed in parallel with the promastigotes to determine
any unspecific parasite death and served as solvent con-
trol. The viable cells that excluded the dye erythrosin B
were then counted at 24 h interval for 7 days under phase
contrast microscope (40 X) in a hemocytometer [16].
Growth reversibility assay
The bioactive fractions of A. indica from the growth kinetics
assay were examined for their cytostatic or cytocidal poten-
tial. Thus, only A. indica leaves ethanolic (ALE) and A. indica
seeds ethanolic (ASE) fractions were included in this assay.
In brief, the treated or untreated parasites were harvested
(7 days post incubation with the bioactive fractions), washed
twice (3000 × g, 10 min, 4°C) with incomplete M199 (with-
out FBS) and finally resuspended in fresh complete M199 at
22°C. After 96 h, the cell viability was ascertained by count-
ing the live promastigotes under the microscope, which were
distinguished from dead cells by erythrosin B staining.
Assessment of 50% promastigote growth inhibitory
concentration (IC50) of the bioactive fractions
Stationary phase promastigotes (2 × 106 ml−1) were incu-
bated with the bioactive fractions or pentamidine or
medium alone at serial three fold dilutions (500 to2.05 μg ml−1). After 96 h, parasite survival was assessed
by enumerating the live cells. Percent (%) viability was
determined in line with the formula:
% Viability ¼ Average viable cell count per ml treated samplesð Þ
Average viable cell count per ml parasite controlð Þ
 100
IC50, the concentration that reduced parasite growth
by 50% was evaluated by graphical extrapolation.
Study of cellular morphology
Morphological alterations in Leishmania parasites post-
treatment with ALE and ASE were studied. In brief, the
L. donovani promastigotes (2 × 106 ml−1) were cultured
without or with ALE, ASE or pentamidine (500 μg ml−1)
for 96 h, following which the parasites were harvested
(3000 × g, 10 min, 4°C) and washed twice with phosphate
buffered saline (PBS, 0.02 M, pH 7.4). The parasites from
all experimental groups were fixed with 80% ethanol,
stained with erythrosin B at room temperature and the
samples observed under Nikon Eclipse 80i microscope
(100 X objective) and the photomicrographs taken. Here,
erythrosin B was employed to stain the cells for optimal
imaging rather than to distinguish live and dead cells.
Phosphatidylserine (PS) exposure in bioactive fractions-
treated promastigotes
To investigate the apoptotic mode of cell death, PS
externalization by means of Annexin –V FLUOS binding
was studied. The assay is based upon the ability of
Annexin-V-conjugated with a flurochrome to bind with PS,
which flips over to the cell surface during apoptosis. To fur-
ther differentiate between apoptotic and necrotic cells, PI
was added as it penetrates the cells with compromised
membrane integrity (dead cells or late apoptotic cells).
Briefly, promastigotes (2 × 106 ml−1) were cultured with the
bioactive fractions or pentamidine (500 μg ml−1) for 72 h.
The treated and untreated cells were harvested (3000 × g,
10 min, 4°C) and washed twice with PBS. Annexin-V
FLOUS and PI staining was performed using Annexin –V
FLUOS staining kit (Roche) according to the manufac-
turer’s instructions. The samples were acquired on a BD
LSR-II flow cytometer and the dot plots of FLUOS fluores-
cence versus PI were recorded. Subsequently, data were
analysed using BD FACS DIVA software.
Detection of DNA fragmentation in bioactive fractions treated
promastigotes by terminal deoxynucleotidyltransferase (TdT)
mediated dUTP (deoxyuridine triphosphate) nick end labeling
(TUNEL) assay
Internucleosomal DNA fragmentation is an index for
apoptosis or programmed cell death (PCD) which can
be detected by TUNEL staining. This assay employs the
use of enzymatic activity of TdT, which incorporates la-
beled dUTP into free 3′-OH (hydroxyl) termini of the
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or without treatment (500 μg ml−1, 72 h) were harvested
(3000 × g, 10 min, 4°C), washed with PBS and fixed with
4% paraformaldehyde for 1 h on ice. The downstream
processing was carried out according to the manufac-
turer’s instructions as described elsewhere [16]. Acquisi-
tion of cells was performed on a BD FACS LSR-II flow
cytometer. Histograms were recorded for each sample
and the shift in mean fluorescence intensity (MFI) along
x-axis (FL-1H, FLOUS fluorescence) in treated cells was
compared with that of untreated labeled promastigotes.
Analysis of cell cycle distributions by propidium iodide
(PI) staining
Cell cycle analysis reveals distribution of cells in three
interphase stages of cell cycle, i.e., G0/G1, S, and G2/M
and also allows the detection of apoptotic cells with frac-
tional DNA content which was quantified by staining with
PI according to Sarkar et al., [17] with few modifications.
In brief, the promastigotes were either cultured in the
presence or absence of bioactive fractions (500 μg ml−1)
along with appropriate controls for 72 h. The promasti-
gotes were harvested (3000 × g, 10 min, 4°C), washed
twice with PBS followed by fixation with 80% chilled etha-
nol and kept at 4°C at least for 24 h. The fixed cells were
harvested, washed twice with PBS, and incubated with
RNase (200 μg ml−1) for 1 h at 37°C and stained with PI
(50 μg ml−1) for 20 min in dark at 22–25°C. The cells were
acquired using a BD LSR II flow cytometer and cytofluori-
metric analysis of cell cycle distributions was done using
BD FACS DIVA software.
Determination of Mitochondrial Membrane Potential
Alterations in mitochondrial membrane potential (Ψm)
were depicted flow cytometrically using a cell permeable
dye JC-1 (5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzi-
midazolylcarbo-cyanineiodide). In live normal cells, JC-1
accumulates and aggregates in mitochondria and emits
red fluorescence at 590 nm. Whereas, in the cells under-
going apoptosis, where there is disruption of mitochon-
drial membrane; JC-1 exists in cytoplasm as monomers,
emitting green fluorescence (530 nm). Thus, the fluores-
cence intensity ratio 590/530 nm typically represents
relative Ψm of a cell. Briefly, to assess the changes in
Ψm, L. donovani promastigotes (2 × 106 ml−1) after treat-
ment with ALE, ASE and pentamidine (500 μg ml−1), were
harvested (3000 × g, 10 min, 4°C), washed twice with PBS
and stained with JC-1 (10 μg, 10 min, 37°C). The cells
were again washed twice with PBS followed by acquisition
in a BD LSR II flow cytometer [18].
Detection of intracellular reactive oxygen species (ROS)
Intracellular ROS generation induced by the bioact-
ive fractions was monitored by H2DCFDA (2′, 7′-dichlorodihydrofluorescein-diacetate) staining. L. donovani
promastigotes (2 × 106 ml−1) were incubated without or
with the bioactive fractions (500 μg ml−1) at 22°C for 72 h.
Cells were washed twice with PBS, and incubated with
H2DCFDA (10 μM) at room temperature in dark. After
15 min, the intensity of fluorescent signal of each sample
was acquired in a BD LSR II flow cytometer and the
MFI was recorded and represented in the form of re-
spective histograms.
Assessment of anti-amastigote activity ex vivo
To determine the antileishmanial efficacy of A. indica
fractions, macrophage-like cell line RAW 264.7 was par-
asitized with L. donovani promastigotes and treated with
ALE or ASE. In brief, RAW macrophages (5 × 106 ml−1,
100 μl per well in RPMI-1640 medium) were plated on
round cover slips (13 mm diameter, Himedia) that were
placed in 24-well plates (Corning) for 24 h in a carbon
dioxide incubator (5% CO2) at 37°C. The coverslips were
washed thrice with serum free RPMI 1640 to remove the
non-adherent cells. The cells were infected with promasti-
gotes in stationary-phase at a ratio of 1: 10 (macrophage:
Leishmania) for 24 h. Cellular monolayers were washed to
remove the non-phagocytosed promastigotes. Infected
macrophages were either incubated in media alone (infec-
tion control) or with serial four-fold dilutions of ALE,
ASE or pentamidine to achieve final concentration be-
tween 200 to 3.12 μg ml−1. After 48 h, the cover slips were
washed with PBS, dried, fixed with chilled methanol,
giemsa-stained and examined under light microscope. A
minimum of 200 macrophages were counted per cover
slip to determine the number of resident amastigotes. Per-
cent reduction was determined using the formula:
% Reduction ¼
Number of amastigotes per
200 macrophages treated samplesð Þ
Number of amastigotes per
200 macrophages infected controlð Þ
 100
IC50, the drug concentration that is cytotoxic to 50%
of the amastigotes, was calculated by plotting the per-
cent reduction in amastigotes against drug concentra-
tions tested [19].
Cytotoxic potential of the bioactive fractions and
determination of selectivity index (SI)
The cytotoxicity of ALE and ASE against mammalian
macrophages was measured by MTT [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay on
RAW 264.7 cells. Briefly, macrophages (2 × 106 ml−1) in
RPMI 1640 were seeded in 96 well tissue culture plates
(200 μl well−1) for 24 h in a CO2 incubator (5% CO2,
37°C). The non-adherent cells were washed away with
incomplete media and the adherent macrophages were
Table 1 Experimental design for in vivo studies
Group 1 (Normal) Normal control/ Naïve mice (Administered PBS only)
Group 2 (INF) Infected control (BALB/c mice infected with
L. donovani promastigotes and administered PBS)
Group 3 (VC) Vehicle control (0.5% DMSO in PBS, the highest
concentration used to dissolve the fractions/
compounds)
Group 4 (AmB) Amphotericin B administered intravenously
(i.v.) at (5 mg/kg bw)
Group 5 (ALE100) ALE administered intraperitoneally (i.p.) at
100 mg/kg bw
Group 6 (ALE 200) ALE administered i.p. at 200 mg/kg bw
Group 7 (ASE100) ASE administered i.p. at 100 mg/kg bw
Group 8 (ASE200) ASE administered i.p. at 200 mg/kg bw
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(0 to 500 μg ml−1) at serial two fold dilutions in triplicates
for 48 h. MTT (5 mg ml−1, 50 μl well−1) was added for fur-
ther incubation of 4–6 h in a CO2 incubator. Following in-
cubation, the plate was centrifuged (400 × g, 20 min, 4°C)
and the supernatant was aspirated. The resulting forma-
zan precipitate was dissolved in isopropanol: dimethylsulf-
oxide (1:1). The relative amount of formazan produced by
the viable cells was quantified spectrophotometrically at
570 nm in an ELISA plate reader. The absorbance of un-
treated macrophages was considered as 100%. Percent via-
bility for different experimental groups was calculated as:
% Viability ¼ Mean specific absorbance treated samplesð Þ
Mean specific absorbance control samplesð Þ
 100
Dose response curves were plotted and concentration of
fractions that is cytotoxic to 50% macrophages (CC50) was
obtained through graphical extrapolation. CC50 concentra-
tion thus obtained was used to determine SI, which is de-
fined as specificity of the bioactive fractions, against
internalized amastigotes over host macrophages. SI was cal-
culated according to the formula:
SI ¼ CC50 against macrophages
IC50 against amastigotes
GC-MS analysis of ALE and ASE
To identify the plant secondary metabolites that may have
contributed to the observed antileishmanial efficacy of ALE
and ASE, GC-MS analysis was performed as described pre-
viously [16] using a Shimadzu QP2010 equipped with a
DB-5MS column (30 m length, 0.25 mm i.d., film thickness
0.25 μm). The column temperature was increased gradually
from 60 to 310°C at 5°C min−1, and the injector and de-
tector temperature was 260°C. Helium was employed as
the carrier gas, set at a constant flow rate of 1.5 ml min−1.
The mass spectrums were produced in an electron impact
ionization mode of 70 eV and the chemical constituents
identified after correlation of the recorded mass spectra
with the reference spectra of WILEY8.LIB and NIST08.LIB
library, supplied with the software of the GC-MS system.
In vivo experimental plan
For infection, stationary phase L. donovani promastigotes
were administered intravenously to 6 to 8-week old female
BALB/c mice (2.5 × 107/animal). Ten weeks post-infection,
parasite load was verified in three randomly selected ani-
mals by microscopic examination of giemsa-stained tissue
smears of liver and spleen as well as parasite transform-
ation from splenocytes after which, the mice were arbi-
trarily assorted into different groups (n = 5 in each
group) and the treatment was initiated on the next day
according to the regime (Table 1). Treatment wascarried out for 2 weeks daily at the mentioned doses
except for amphotericin B (AmB, a known antileishma-
nial drug), which was administered alternatively over a
period of 10 days at the indicated dose. Mice were bled
2 weeks post treatment and sacrificed for assessment
of infection and study of different immunomodulatory
and toxicity parameters.
Assessment of organ parasite burden
To assess the in vivo efficacy of A. indica bioactive frac-
tions, hepatic and spleen parasitic load was determined
in treated and untreated animals. Mice were euthanized
at 2 weeks post treatment and liver and spleen weights
were measured. Small pieces of tissue each from liver
and spleen were incised to prepare impression smears.
The tissue impressions were dried, fixed with chilled ab-
solute methanol and subsequently giemsa-stained. The
parasite burden was evaluated as Leishman-Donovan
Units (LDU) according to the formula [20]:
Number of amastigotes
Number of macrophages
 organ weight mgð Þ
Further, percent protection rendered by the different
treatment groups was calculated according to the formula:
LDUinfected control – LDUtreated
LDUinfected control
 100
Preparation of leishmanial antigens
Leishmania freeze thawed antigen (FT) was prepared
from stationary phase promastigotes. Briefly, the promasti-
gotes (108 ml−1) were harvested, washed twice with PBS
and subjected to 6 cycles of alternate freezing (at −70°C,
30 min) and thawing (37°C, 15 min) followed by estimation
of protein concentration by Folin and Lowry method [21].
Soluble leishmanial antigen (SLA) was prepared similarly
with some additional modifications. Parasites (108 ml−1)
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followed by centrifugation at 5250 × g for 30 min [22]. The
resultant supernatant was separated and protein concentra-
tion determined. The antigens were stored at −70°C until use.
Evaluation of delayed type hypersensitivity (DTH) responses
It is well established in leishmaniasis that successful cure
results in transition from DTH-negative to DTH-positive
state. Thus, DTH response which serves as a marker of
CMI was measured in all the test animals two weeks
post-treatment. Briefly, mice right and left hind foot
pads were inoculated intradermally with FT (800 μg ml−1)
and PBS alone, respectively [23]. Footpad swelling was
measured after 24 h of antigen inoculation by a vernier
calipers and the DTH response (mm) was measured as
the mean difference between the footpad swelling of two
hind footpads.
Detection of serum IgG isotypes
The production of immunoglobulin G (IgG) isotypes dir-
ectly relates to the induction of T-helper (Th) subsets of
CD4+ T cells, which defines the outcome of immune
response via polarization towards either cellular (Th1)
or humoral immune response (Th2). Thus, to assess
whether our fractions activated CMI, serum levels of
IgG isotypes, IgG2a and IgG1 were assessed by means of
ELISA. Briefly, mice were bled 2 weeks post treatment
and the sera was separated and stored at −70°C until
use. 96 well U-bottom plates (Corning) were coated with
FT (25 μg ml−1) and left overnight at 4°C. To remove
unbound antigen, the plates were gently washed
(2 min × 3 times) with washing buffer (PBS with 0.05%
Tween-20) and the non-specific sites were blocked by
1% BSA in PBS for 3–4 h at room temperature. After
washing, the plates were incubated with mice sera (1:
1000, diluted in PBS) overnight followed by washing to re-
move unbound primary antibodies. The plates were then
incubated with secondary antibodies, goat anti-mouse
IgG2a and IgG1 (Sigma) followed by washing and further
incubation with tertiary antibody, i.e., rabbit anti-goat IgG
conjugated with horse radish peroxidase (1: 10,000). The
plates were again washed with washing buffer thrice and
finally with PBS followed by addition of the substrate solu-
tion (o-phenylenediamine dihydrochloride, 0.8 mg ml−1 in
phosphate citrate buffer, pH 5.0 with 0.04% H2O2). The
plates were incubated for 5 min and read at 450 nm in an
ELISA reader [24].
Quantification of nitric oxide (NO)
Th1 cells activate nitric oxide synthase II (NOS II) medi-
ated conversion of L-arginine into NO and citrulline. NO
is a potent cytotoxic molecule majorly responsible for
containing intracellular parasites including Leishmania. In
cell culture, NO is detected in the form of nitrite which isone of the two primary, stable and non-volatile products
of NO. Briefly, splenocytes from all experimental groups,
unstimulated or primed with SLA (12 μg ml−1) were incu-
bated for 48 h as described above. The culture superna-
tants were harvested, to which an equal volume of Griess
reagent [1% sulphanilamide and 0.1% N-(1-naphthyl)
ethylenediamine dihydrochloride in 5% H3PO4] was added
and the plates incubated for 10 min at room temperature
followed by absorbance measurement in ELISA plate
reader at 540 nm. The nitrite levels in the different experi-
mental groups were quantified with respect to the stand-
ard curve generated with sodium nitrite.
Determination of lymphoproliferative response
To study the in vitro recall response, lymphoprolifera-
tion as an index of CMI was evaluated in spleen cells by
labeling with carboxyfluorescein succinimidyl ester
(CFSE). Briefly, animals from all the experimental groups
were euthanized 2 weeks post-treatment and the spleens
were aseptically removed. Single cell suspension of the
spleen was prepared in RPMI-1640 incomplete media
and filtered through 0.22 μm nylon mesh (BD Biosci-
ences). The red blood cells (RBCs) were lysed with ice-
cold lysis buffer (20 mM Tris buffered with 0.14 M
NH4Cl). After several washes with incomplete RPMI
medium (without FBS), the viable cells were counted
after trypan blue dye exclusion. CFSE staining procedure
was followed according to Del-Rey et al., [25] with few
modifications. The splenocytes at a cell density of 5 ×
106 cells ml−1 were incubated with 1 μM of CFSE, in
dark at room temperature for 15 min, and the reaction
was quenched with ice cold complete RPMI-1640 media
(with 10% FBS). The cells were washed twice with the
same medium and seeded in 96 well flat bottom plates
(Corning). The cells were re-stimulated in vitro either
with medium alone or with SLA (12 μg ml−1) or with
Concanavalin A (ConA, 5 μg ml−1), a non-specific mito-
gen inducer, taken as positive control. After 48 h, the
cells were washed twice with PBS and finally resus-
pended in PBS. 50,000 cellular events were acquired for
each sample in a flow cytometer, histograms were plot-
ted and the percentage of cells undergoing proliferation
was deduced from the histogram statistics.
Study of CD4 and CD8 T cell expression profile
Since CD4 as well as CD8 T cells are essential to suc-
cessful cure of leishmaniasis, CD4 and CD8 T cell popu-
lations were characterized in splenocytes by surface
phenotyping. Briefly, 2 weeks post treatment, the spleens
were homogenized to single cell suspension in RPMI
1640 medium and the RBCs lysed as described above.
After sufficient washings, the live cells excluding trypan
blue were enumerated. A total of 2 × 106 cells per tube
were taken for downstream processing. The cells were
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subsequently stained with antimouse-CD4-phycoerythrin
(PE) and antimouse-CD8-fluorescein isothiocyanate (FITC)
antibodies diluted (1: 200) in the same buffer for 15 min in
dark on ice. Following incubation, the cells were washed
twice and finally acquired in a BD LSR II flow cytometer.
Suitable isotype controls were also included to rule out
background fluorescence. Dot plots were generated and
quadrants were set, quadrant statistics revealed the percent-
age of each positive population [26].
Immunostimulatory effect of ALE and ASE on macrophages
Co-stimulatory molecules present on antigen presenting
cells (APCs) play a pivotal role in outcome of leishmania-
sis since T cell-mediated activation of APCs is largely
dependent on proper functioning of these molecules
owing to their contribution in T cell receptor-major histo-
compatibility complex (MHC) interactions. Thus, the ex-
pression of CD80 and CD86 co-stimulatory molecules
was studied in peritoneal cavity derived macrophages, 2
weeks post-treatment. Animals from different experimen-
tal groups were sacrificed and macrophages were drawn
from peritoneal cavity aseptically in incomplete RPMI-
1640 medium. The cells were washed twice with incom-
plete medium and 2 × 106 macrophages per tube were
taken and washed with FACS buffer. The same buffer was
used for all subsequent washings and to prepare antibody
dilutions. Following two washes, the cells were co-stained
with Allophycocyanin (APC) conjugated antimouse-
CD80, antimouse-CD86-PeCy7 (a tandem fluorochrome)
(1: 200 dilution). Single flurochrome controls and isotype
controls were accordingly prepared to assess the staining
intensity and background staining as well as to adjust the
compensation. Staining procedure was carried out in dark
for 15 min on ice followed by two subsequent washes and
acquisition of cells in a BD LSR II flow cytometer.
Detection of Th1/Th2 cytokines
Shift in pro-inflammatory and anti-inflammatory cytokine
secretion patterns can directly determine the outcome of
Leishmania infection. Hence, the Th1/Th2 cytokines levels
were determined in culture supernatant of splenic lympho-
cytes. Briefly, lymphocytes from spleens of untreated and
treated animals were pulsed in vitro with 12 μg ml−1 of SLA
in a humidified atmosphere at 37°C. Post 48 h, the culture
supernatant from all the experimental groups was harvested
and stored at −70°C until analysis for INF-γ, TNF-α, IL-2,
IL-4 and IL-10 using mouse flex set, BD cytometric bead
array in accordance with the manufacturer’s instructions [23].
Estimation of in vivo toxicity of ALE and ASE on liver and
kidney functions
To assess the in vivo toxicity of bioactive fractions, naïve
mice (5 per group) were injected with ALE, ASE (i.p)and AmB (i.v) as per earlier described regimen. The mice
were dosed continuously for 14 days and 2 weeks post-
treatment, the mice were bled to obtain serum samples.
To evaluate the side effects on liver function, serum glu-
tamate pyruvate transaminase (SGPT), serum oxaloacetate
transaminase (SGOT) and alkaline phosphatase (ALP)
were measured using commercially available kits (Span
Diagnostics Ltd., Surat, India). To determine the adverse
effects of the bioactive fractions on kidney function, urea
and creatinine concentrations were estimated in the re-
spective serum samples by commercially available kits
(Span Diagnostics Ltd., Surat, India) according to the
manufacturer’s instructions.
Statistical analysis
All in vitro experiments were replicated at least thrice in
triplicate and the results depicted are from one of the
three independent experiments and expressed as mean ±
standard error of mean (SEM) of samples. The in vivo
study was carried out twice with 5 mice per group, and
the data are from one of the two independent experiments
and expressed as mean ± SEM. Statistical analysis was per-
formed using Graph-Pad Prism 5 software and the statis-
tical significance was calculated by one-way analysis of
variance (ANOVA) followed by Tukey’s multiple compari-
son test. Differences were considered statistically signifi-
cant at P < 0.05.
Results
ALE and ASE inhibit the growth of L. donovani
promastigotes
The growth inhibitory effect of A. indica leaves, bark and
seed fractions was assessed against exponentially growing
L. donovani promastigotes. ALE and ASE reduced the pro-
liferation of L. donovani promastigotes in a time-dependent
manner with ALE being more effective in reducing the
parasite growth than ASE (Figure 1a). A. indica bark hex-
ane fraction (ABH) initially suppressed parasite multiplica-
tion, but a gradual increase in cell density was evident.
None of the other fractions caused significant decline in
parasite viability. Pentamidine, an established antileishma-
nial compound rapidly eliminated Leishmania parasites
in vitro. Parasites without any treatment or with 0.5%
DMSO (data not shown) proliferated at normal rates con-
firming the inertness of the solvent.
ALE and ASE induced mode of parasite killing is
leishmanicidal
To determine whether the mode of ALE and ASE induced
parasite death is leishmanistatic or leishmanicidal, the para-
sites from different experimental groups (after incubation
for 7 days) were washed to remove the test fractions/
compounds and were further incubated for 96 h in fresh
complete medium. Marginal number of parasites reverted
Figure 1 Antileishmanial effect of A. indica fractions on L. donovani promastigotes. (a). Growth Kinetics Assay. 2 × 106 ml−1 stationary
phase promastigotes were grown in the presence of different A. indica fractions: A. indica leaves hexane (ALH), ethanol (ALE) and aqueous (ALA);
A. indica bark hexane (ABH), ethanol (ABE) and aqueous (ABA); A. indica seeds hexane (ASH), ethanol (ASE) and aqueous (ASA). Additional
experimental groups included parasite control (without any treatment), and pentamidine. ***P < 0.001 in comparison to parasite control.
(b). Growth Reversibility Analysis. L. donovani promastigotes (2 × 106 ml−1) were incubated with ALE, ASE, pentamidine and DMSO (solvent
control, 0.5%) and growth reversal after drug treatment was analyzed as described in Methods. ***P < 0.001 with respect to parasite control.
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P < 0.001) and ASE (0.57 × 106 ml−1 ± 0.013, P < 0.001)
treated samples, in comparison to control without treat-
ment and as well as vehicle control (treated with 0.5%
DMSO), indicating that the mode of cell death is predom-
inantly cytocidal in nature. In pentamidine treated samples,
no reversion in parasite growth was observed (Figure 1b).
IC50 of bioactive fractions on promastigotes
IC50 was determined after incubation of L. donovani par-
asites with various concentrations of ALE, ASE or pent-
amidine. Treatment of L. donovani promastigotes with
ALE and ASE resulted in a dose-dependent repression
of parasite growth and IC50 was attained at 34 μg ml
−1
and 77.66 μg ml−1, respectively while that of pentami-
dine was 1.4 μg ml−1 (Figure 2a and Table 1).ALE and ASE induce morphological alterations in
L. donovani promastigotes
Morphological analysis of L. donovani promastigotes after
treatment with the bioactive fractions revealed charac-
teristic differences amongst the untreated and treated
parasites. The untreated parasites retained their classical
morphology being slender, elongated and flagellated
(Figure 2b). In ALE treated promastigotes, changes per-
taining to shape and size were observed. The cells be-
came oval and exhibited an atypical appearance owing
to substantial reduction in size, and shortening of fla-
gella. ASE also induced similar changes in L. donovani
promastigotes, though few cells retained their native
morphology. Pentamidine treatment also resulted in a
loss of prototypical morphology, with cells becoming
oval and shrunken with degenerated flagella.
Figure 2 Elaboration of anti-promastigote efficacy of A. indica fractions. (a). IC50 determination against L. donovani promastigotes.
L. donovani promastigotes (2 × 106 ml−1) were incubated with different concentrations of ALE, ASE and pentamidine as described in Methods.
Each point corresponds to the mean ± SE of samples in triplicate and data is from one of three independent experiments. (b). Light microscopy
analysis of promastigote morphology. Promastigote forms of L. donovani were treated with ALE, ASE and pentamidine (500 μg ml−1) and
stained with erythrosin B. Photomicrographs were recorded at 100 X under oil immersion.
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To ascertain the apoptotic or necrotic mechanism of
induced cell death by ALE and ASE, bioactive fractions-
treated promastigotes were co-stained with Annexin
V-FLUOS and PI. Following treatment with ALE and
ASE, 4.7% and 4.5% cells were found to be Annexin-V
positive or apoptotic, respectively (lower right quadrant).
1.4% (ALE) and 1.0% (ASE) cells were found to be second-
ary apoptotic (the cells which first undergo apoptosis
followed by disruption of cell membrane) as depicted in
upper right quadrant. 0.8% (ALE) and 0.3% (ASE) cells were
also observed to be PI positive (upper left quadrant). Thus,
our results indicated that ALE and ASE exerted their
antileishmanial activity primarily via apoptosis (Figure 3a).
Pentamidine treatment resulted in extensive PS externalization
with 45.4% cells being Annexin-V positive.
ALE and ASE treatment cause DNA fragmentation
The DNA fragmentation, one of the hallmark traits of
apoptosis, has been documented through TUNEL labeling,
wherein the 3′OH groups are generated in abundance
and serve as substrate for Tdt mediated fluorescence
conjugated-dUTP binding. The histogram analysis revealedthat whilst a small percentage of cells were TUNEL
positive with mean fluorescence intensity (MFI) = 76 ±
14.0, in the promastigotes without any drug treatment,
with and after pentamidine treatment, the MFI recorded
was 777 ± 32.0 (P < 0.001). In ALE and ASE treated sam-
ples, the MFI increased to 516 ± 74.5 (P < 0.01) and 499 ±
43.66 (P < 0.01), respectively with respect to parasite con-
trol demonstrating apoptosis inducing capacity of the
bioactive fractions (Figure 3b).
ALE and ASE induce an amplification in sub G0-G1
population
Cell cycle analysis depicts the effect of different treatments
on progression of cell cycle wherein presence of cells in
sub G0-G1 phase indicates the occurrence of apoptosis.
ALE and ASE triggered apoptosis in L. donovani promas-
tigotes with an increase in sub G0-G1 population to
23.6% ± 0.75 (P < 0.001) and 20.8% ± 0.69 (P < 0.001), re-
spectively in comparison to untreated parasite control
where only 0.2% ± 0.05 cells were found to be apoptotic.
Pentamidine treatment also resulted in an upsurge in per-
centage of apoptotic cells with 28.2% ± 1.15 (P < 0.001)
cells in the sub G0-G1 phase (Figure 4).
Figure 3 Assessment of apoptosis inducing potential of bioactive fractions. (a). Determination of PS externalization in treated promastigotes.
L. donovani promastigotes (2 × 106 ml−1) were treated with 500 μg ml−1 of ALE, ASE and pentamidine for 72 h and dual-stained with Annexin-V-FLUOS
and PI. The lower left quadrant represents live cells, upper left quadrant = PI positive, necrotic cells, lower right quadrant = Annexin-V-FLUOS positive,
apoptotic cells, upper right quadrant = PI and Annexin positive, late apoptotic cells. The percentage of positive cells is shown in the respective
quadrants. (b). Probing of in situ DNA fragmentation by TUNEL assay. L. donovani promastigotes (2 × 106 ml−1) were incubated in the absence
or presence of ALE, ASE, and pentamidine (500 μg ml−1) for 72 h. The samples were processed according to instructions provided with
ApoDirect kit (Roche), as described in Methods. ***P < 0.001 and **P < 0.01, in comparison to parasite control.
Chouhan et al. Parasites & Vectors  (2015) 8:183 Page 10 of 24Bioactive fractions treatment depolarize mitochondrial
membrane
The disruption of mitochondrial membrane potential
(Ψm) is an attribute of apoptosis. Since, hemoflagellate
protozoans possess a single mitochondrion; loss of
mitochondrial function becomes all the more critical for
the survival of organism. To detect the changes in Ψm,
JC-1 was used and the fluorescence intensity ratio ob-
tained at 590 and 530 nm was determined as an indica-
tor of transmembrane Ψm. In our study, ALE and ASE
induced mitochondrial membrane depolarization as
evidenced by fall in 590/530 nm ratio to 4.15 ± 0.16
(P < 0.01) and 5.41 ± 0.44 (P < 0.01), respectively versus
untreated cells (15.03 ± 1.98). Pentamidine induced sub-
stantial depolarization by decreasing the 590/530 nm ra-
tio to 0.84 ± 0.08 (Figure 5a).
Treatment with bioactive fractions induce ROS generation
To examine the ROS generation post treatment with
ALE and ASE in L. donovani promastigotes, H2DCFDA
was used which fluoresce green upon cleavage with
OH radicals and H2O2. The significant shift (P < 0.001
for all experimental groups) in mean fluorescence in-
tensity (Figure 5b) in case of ALE (MFI = 10,037 ±
141.5) and ASE (MFI = 9935 ± 166) treated samples incomparison to untreated cells (MFI = 3481 ± 168) clearly
depicted that ALE and ASE treatment successfully stim-
ulated ROS production in L. donovani promastigotes.
ROS production was also observed following treatment
of L. donovani promastigotes with pentamidine (MFI =
10,656 ± 92).
ALE and ASE reduce intra-macrophagic amastigote viability
Upon entering the mammalian host, Leishmania para-
sites transform into the amastigote stage that reside in-
side the phagolysosomal vacuoles of macrophages.
Leishmania amastigotes thus being the biologically and
clinically relevant form, it was imperative to assess the
anti-amastigote potential of our bioactive fractions. Ac-
cordingly, the anti-amastigote efficacy was assessed in
RAW 264.7 macrophages parasitized by L. donovani
promastigotes. There was a dose-dependent decrease in
amastigote burden both with ALE and ASE treatment
and IC50 (μg ml
−1) was achieved at 17.66 ± 2.88 and
24.66 ± 4.98 μg ml−1, respectively. In case of pentami-
dine, IC50 was 0.87 ± 0.016 μg ml
−1 (Figure 6a, Table 2).
The reduction in amastigote burden was also visualized
microscopically and was well evident in photomicro-
graphs of giemsa stained untreated and treated macro-
phages (Figure 6b).
Figure 4 Cell cycle analysis by PI staining. L. donovani promastigotes (2 × 106 ml−1) were incubated with ALE, ASE and pentamidine
(500 μg ml−1). After 72 h, the samples were processed for cell cycle as described in Methods. The bar diagram depicts the percentage of cells in
the sub G0-G1 phase. ***P < 0.001 with respect to parasite control.
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Cytotoxic potential of the two bioactive fractions along
with pentamidine was evaluated against RAW 264.7
macrophages to ensure their safety profile. The macro-
phages were incubated with the bioactive fractions at
different concentrations (0–500 μg ml−1) and cell viabil-
ity was assessed via MTT assay in which MTT is enzy-
matically reduced into formazan crystals which is
subsequently dissolved in organic solvent(s) to generate
pink to purple colour. The intensity of the colour pro-
duced is directly proportional to cell viability. With ALE,
the CC50 obtained was 461 ± 7.07 and SI was 26.10.
However, in case of ASE, no adverse cytotoxicity was ob-
served and even at 500 μg ml−1, more than 50% cells
were viable. In case of pentamidine, SI was found to be
51.72 (Figure 6c, Table 2).
GC-MS analysis of ALE and ASE
Plant secondary metabolites present in ALE and ASE,
which may have been responsible for the observed leish-
manicidal effect, were analyzed by GC-MS analysis. The
total compounds detected in ALE and ASE were 49 and
58, respectively out of which the major constituents arelisted in Table 3. The complete GC-MS profile is elabo-
rated in Additional files 1 and 2.
Bioactive fractions reduce liver and spleen parasite
burden
To assess the in vivo antileishmanial potential of ALE and
ASE, 10 weeks-infected BALB/c mice were treated daily
up to 2 weeks with ALE or ASE at 100 and 200 mg/kg bw.
The mice were euthanized 2 weeks post-treatment. The
antileishmanial efficacy was evaluated as fall in liver and
spleen parasite burden and percent protection rendered
by the different experimental groups was determined. As
shown in Figure 7(a), mice that received only vehicle con-
trol (VC) exhibited the lowest levels of protection in liver
as well as spleen, corresponding to 9.33% ± 4.58 and
8.03% ± 3.62, respectively. ALE conferred significant pro-
tection to infected mice (liver = 87.76% ± 7.19, P < 0.001,
spleen = 85.55% ± 9.66, P < 0.001) at 200 mg/kg bw dose.
At lower dose, moderate levels of protection were observed
in the liver (47.19% ± 6.22) and spleen (42.93% ± 7.51)
though the levels were statistically significant in com-
parison to VC (P < 0.001). At 200 mg/kg bw, ASE also
exhibited significant (P < 0.001) and comparable pro-
tective efficacy with protection levels of 85.54% ± 8.8
Figure 5 Impact of ALE and ASE on cellular events leading to induction of apoptosis. (a). Effect of A. indica fractions on Ψm in L. donovani
promastigotes. Untreated and treated parasites (2 × 106 ml−1, 500 μg ml−1) were incubated for 72 h and stained with JC-1 and acquired in a flow
cytometer. Red and green fluorescence positive cells were separately gated and their ratio was represented as relative Ψm values. ***P < 0.001,
**P < 0.01 in comparison to parasite control. (b). ROS generation in L. donovani promastigotes. Leishmania parasites (2 × 106 ml−1) were grown in
the presence or absence of bioactive fractions and pentamidine (500 μg ml−1) for 72 h and stained with H2DCFDA. Data was analyzed in the form
of histograms where a shift in MFI in P2 gated region was recorded.
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lower dose, i.e., 100 mg/kg bw, ASE endowed the lowest
but significant protective efficacy (liver = 44.35% ± 6.88, P
< 0.001, spleen = 42.56% ± 6.98, P < 0.001) of all the treat-
ment groups. AmB, the known antileishmanial drug, in-
duced maximum decrease in hepatic and splenic parasite
burden with 95.61% ± 3.85 and 90.16% ± 6.14 protection,
respectively.
The effectualness of AmB, ALE and ASE in curing
L. donovani infection was also reflected in reduction of liver
and spleen weights when compared to infection control(INF) group. As can be inferred from Figure 7(b and c),
a significant increase in liver and spleen weight was well
evident in INF and VC groups, indicative of heavy para-
site burden in the organs in comparison to the normal
mice. Following treatment with AmB, ALE and ASE, there
was a considerable reduction in hepatic and splenic
weight with respect to INF (P < 0.05). With ALE and
ASE, reduction in liver and spleen weights was dose-
dependent and treatment with higher doses was more
effective in restoring the hepatic and splenic weights in
normal range.
Figure 6 Effect of ALE and ASE on intra-macrophagic amastigotes. (a). Estimation of anti-amastigote efficacy. Parasitized RAW 264.7 macrophages
were cultured with ALE and ASE at different concentrations and percent reduction in amastigote growth was determined as described in Methods.
***P < 0.001in comparison to infected control. (b). Microscopic imaging of L. donovani infected macrophages. Images depict giemsa stained
intracellular amastigote forms residing in RAW macrophages. Arrow indicates the internalized parasites, where a decrease in amastigote number
in treated samples is indicative of their anti-amastigote potential. (c). Cytotoxicity of ALE and ASE against mammalian macrophages. RAW 264.7
cells (2 × 106 ml−1) were incubated with ALE and ASE (0 to 500 μg ml−1) and cell viability was ascertained by MTT assay. Data shown are from
one of the three independent experiments and are expressed as mean ± SEM of samples in triplicates. *P < 0.05, #P < 0.01 with respect to
macrophage control without any treatment.
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mice induces DTH response
Cure of VL is generally concurrent with restoration of
an effective cell-mediated immune response and the
known chemotherapy also concomitantly establishes
parasite clearance and host immune modulation towards
Th1 type [4]. Thus, acquisition of DTH post successful
treatment is a clear indication of Th1 polarization. There-
fore, we evaluated whether the bioactive fractions promoted
DTH responses in L. donovani infected BALB/c mice. Both
ALE and ASE (200 mg/kg bw) exhibited pronounced DTHTable 2 Bioactivity of ALE and ASE against L. donovani proma
macrophages
A. indica fractions/compounds IC50 (μg ml
−1) promastigotes IC
ALE 34 ± 0.81 17
ASE 77.66 ± 3.13 24
Pentamidine 1.4 ± 0.249 0.8
Values represent Mean ± SE, SI = Selectivity Index (calculated as described in Methoreactivity (P < 0.001) with ALE inducing the strongest DTH
response, comparable to AmB (Figure 8a). No significant
induction of DTH response was evidenced in ALE and
ASE (100 mg/kg bw) as well as in VC group.
Bioactive fractions treatment results in enhanced IgG2a
levels and decline in the production of IgG1 antibodies
IgG2a (induced by INF-γ) and IgG1 (induced by IL-4)
serve as surrogate markers for Th1 and Th2 activation,
respectively. Sera from ASE (200 mg/kg bw) treated
mice contained the highest levels IgG2a that was 4.9 foldstigotes and amastigotes as well as RAW 264.7
50 (μg ml
−1) amastigotes CC50 (μg ml
−1) macrophages SI
.66 ± 2.88 461 ± 7.07 26.10
.66 ± 4.98 >500 -
7 ± 0.17 45.0 ± 2.80 51.72
ds), “-” indicates that SI could not be determined.
Table 3 Major constituents of ALE and ASE as identified
by GC-MS
S. no. RT %Area Compound
ALE
1 39.212 25.21 1,2-Benzenedicarboxylic acid
2 47.709 16.95 Stigmasterol acetate
3 29.394 7.90 Palmitic acid
4 48.222 7.47 Ergosterol acetate
5 32.636 5.90 Cis,cis,cis-7,10,13-Hexadecatrienal
ASE
1 32.938 12.96 (E)-9-Octadecenoic acid ethyl ester
2 49.151 10.45 19-Hydroxyandrost-5-en-3-yl acetate
3 9.353 8.56 1,2,3-Propanetriol
4 32.775 7.40 Linoleic acid
5 39.183 7.14 1,2-Benzenedicarboxylic acid
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AmB (4.8 fold, P < 0.01) and ALE (4.6 fold, P < 0.05).
The lower doses of bioactive fractions also stimulated
the production of IgG2a. ASE and ALE (100 mg/kg bw)
induced 3.9 and 3.2 fold, respectively more IgG2a anti-
body than infected mice, however the difference was not
statistically significant. Antigen specific IgG1 levels were
elevated in INF and VC groups in comparison to the un-
treated mice (P < 0.001). IgG1 level was substantially re-
duced in treated groups (P < 0.05) with little variation
amongst the two doses (P < 0.05) (Figure 8b).
Resolution of leishmaniasis by ALE and ASE is mediated
by NO production
Leishmania impairs NO generation, which is the principle
microbicidal molecule produced by macrophages in re-
sponse to Th1 cytokines. Th1 polarization in ALE and
ASE treatment correlated with increase in NO production.
Minimal levels of NO were detected in naïve mice
(5.07 μM). ALE (200 mg/kg bw) treatment led to max-
imum NO production, 29.57 μM versus 7.85 μM as de-
tected in infection control group (P < 0.001). NO was also
induced by ASE (24.64 μM, P < 0.01) at 200 mg/ kg bw. At
100 mg/kg bw, both ALE and ASE elevated nitrite levels
to 19.38 μM and 18.23 μM, respectively which was non-
significant in comparison to infection control. AmB treat-
ment also resulted in upregulation of NO production to
27.38 μM (P < 0.001) (Figure 8c).
ALE and ASE treatment induce lymphoproliferation in
L. donovani infected BALB/c mice
During active VL, T cells are driven towards anergy to leish-
manial antigens, denoting defective CMI. Thus, we were
prompted to evaluate T cell proliferation responses in
splenocytes of L. donovani infected mice. Proliferation of Tcells after treatment with different groups was estimated by
CFSE labeling of splenocytes. Since, CFSE intensity is re-
duced by half at each cell division; CFSE dilution assay pro-
vides an apparent measure of cell proliferation. Splenocytes
from different experimental groups were in vitro re-
stimulated with SLA and post 48 h of CFSE labeling, the
cells were analyzed by flow cytometry. The percentage
of normal cells (without SLA stimulation) that under-
went division was 22.2% ± 1.34. SLA stimulated normal,
infection control and VC groups exhibited 23.6% ± 0.28,
25.0% ± 0.31, and 27.0% ± 0.89 lymphoproliferation, re-
spectively. Con A stimulated normal cells exhibited the
highest lymphoproliferative response with 50.8% (±3.18)
dividing cells. ALE (200 mg/kg bw) showed enhanced T
cell proliferation (44.8% ± 1.90, P < 0.01) followed by
ASE (38.5% ± 1.60, P < 0.01) upon in vitro restimulation
with SLA. At 100 mg/ kg bw both ALE (27.6% ± 7.85)
and ASE (24.2% ± 3.31) exhibited only partial lympho-
proliferative response. Splenocytes from AmB treated
mice also demonstrated stimulation of T cells with
45.7% (±0.93) cells undergoing division (Figure 9).
ALE and ASE treatment induce increase in number of
T lymphocytes
As T cells contribute in resolving visceral infection,
phenotypic analysis of CD4+ and CD8+ T lymphocytes
of spleen was performed by flow cytometry. Spleen cells
from different treatment groups were isolated, stained
with antimouse-CD4-PE and antimouse-CD8-FITC,
followed by acquisition in a flow cytometer along with
appropriate controls. As deduced from quadrant statis-
tics, the CD4+ and CD8+ T cells expressing individual
populations were 23.6% ± 1.4 and 10.7% ± 0.8, respect-
ively in naïve mice, which was down modulated in in-
fected mice (CD4+ = 21.5 ± 1.2, CD8+ = 6.3% ± 1.5). All
the treatment groups augmented CD4+ T cell population
(Figure 10), with AmB resulting in maximum modulation
(36.7% ± 1.10, P < 0.001). A comparable increase (35.8% ±
1.12, P < 0.001) was observed in ALE (200 mg/kg bw)
treated mice. ASE treatment also induced pronounced
elevation in CD4+ phenotype by increasing the popula-
tion up to 34% ± 0.67 (P < 0.01). At lower dose of ALE
and ASE, CD4+ percentage was restored to normalcy
(ALE = 26.5% ± 1.85, ASE = 25.7% ± 0.76). AmB treat-
ment reinstated the CD8+ population to normal level
(10% ± 1.25). ALE (200 mg/kg bw) demonstrated an en-
hanced expression (14.2% ± 1.12, P < 0.01) whereas at
100 mg/kg bw, CD8+ population was found to be 13.1% ±
2.9 (P < 0.01). In case of ASE treatment, 100 mg/kg bw
dose restored the CD8+ expression to normal range
(10.1% ± 1.1) whereas 200 mg/kg bw dose upregulated the
percentage of CD8+ population to 12.2% ± 1.6 (P < 0.05).
Thus, the data indicates immunopotentiating effects of
ALE and ASE.
Figure 7 In vivo antileishmanial efficacy of A. indica fractions. (a). Determination of parasite burden. 10 weeks infected BALB/c mice were
treated with ALE, ASE and AmB and were assessed for parasite burden 2 weeks post treatment as described in Methods. Graph depicts percent
protection exhibited by the different treatment groups. ***P < 0.001 in relation to vehicle control for both liver and spleen experimental data.
VC = Vehicle control, AmB = Amphotericin B, ALE100 = ALE at 100 mg/kg bw, ALE200 = ALE at 200 mg/ kg bw, ASE100 = ASE at 100 mg/kg bw,
ASE200 = ASE at 200 mg/ kg bw. (b) Reduction in liver weight after treatment with bioactive fractions. 2 weeks post treatment, all the animals
were sacrificed and intact livers were surgically isolated and weighed to assess the variation amongst the different experimental groups. #indicates
significant (P < 0.001) enhancement in liver weight in INF and VC groups in comparison to normal mice. For all other groups ***P < 0.001, **P < 0.01,
and *P < 0.05 in relation to infection control group. (c) Restoration of spleen weight after treatment with ALE and ASE. Spleen from all the animals
were isolated and weighed aseptically to determine any changes following ALE and ASE treatment. # denotes P < 0.001 for INF and VC control group
with respect to naïve mice. ***P < 0.001, **P < 0.01 and *P < 0.05 in comparison to INF group.
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of CD80/CD86
Interaction between T cell receptor and MHC is strength-
ened via co-stimulatory molecules, CD80 (B7.1) and
CD86 (B7.2). The percentage of macrophages expressing
CD80 and CD86 was upregulated following treatment
with the bioactive fractions. ALE (200 mg/kg bw) elevated
CD80 and CD86 expression profile to 55.5% (P < 0.001)
and 28.8% (P < 0.001), respectively in comparison with
infection control (CD80 = 34.9%, CD86 = 13%). ASE at
200 mg/kg resulted in significant increase in expression
of CD80 and CD86 to 54.9% (P < 0.001) and 27.6%
(P < 0.001), respectively. Whereas, at 100 mg/kg bw,
the CD80 expression was enhanced up to 46.4% (P < 0.01)
and 42.7% (P < 0.05), respectively with ALE and ASE.Treatment at 100 mg/kg bw resulted in partial modulation
of CD86 expression. CD86 was restored to normal levels
with both ALE (18.7%) and ASE (18.5%) at 100 mg/kg
bw and the changes were not significant in relation to
infection control (P > 0.05). AmB treatment particularly
enhanced the CD80 and CD86 expression up to 53%
(P < 0.001) and 22.8% (P < 0.01), respectively with respect
to infection control. In macrophages from naïve mice, the
levels of CD80 and CD86 were 37.5% and 14.2%, respect-
ively (Figure 11a and b).
Bioactive fractions induced production of Th1 cytokines
Th1/Th2 cytokine levels were quantified in culture su-
pernatants of spleen cells from all the experimental
groups. Animals treated with 200 mg/kg bw of ALE and
Figure 8 Assessment of Th1 modulatory potential of ALE and ASE. (a). Evaluation of DTH response as an index of CMI. DTH responses were
measured 2 weeks post treatment with the bioactive fractions and AmB. The response is expressed as difference (mm) between the thickness of
right food pad (injected with 800 μg ml−1 of FT) and the left foot pad (injected with PBS), measured after 24 h. ***P < 0.001 with respect to INF,
ns-not significant. (b). Serum levels of IgG isotypes in bioactive fractions treated BALB/c mice. At 2 weeks post-treatment, the serum samples
from different groups were assayed for Leishmania antigen specific IgG2a and IgG1 antibodies by ELISA. ***P < 0.001, **P < 0.01 and *P < 0.005
with respect to INF. # indicates statistical significance in INF and VC groups with respect to normal control in IgG1 plots. (c). Estimation of NO
generation in vivo. NO was quantified as nitrite by Griess reaction in supernatants of SLA-stimulated splenocytes derived from the indicated
groups. ***P < 0.001, **P < 0.01 and ns-not significant with respect to infection control.
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IL-2 with respect to infection control (P < 0.05). High
concentrations of Th2 cytokines, IL-4 and IL-10 were
observed in infection control group (P < 0.001) in com-
parison to naïve mice and a profound decline in IL-10
and IL-4 levels was witnessed in ALE and ASE treated
groups (P < 0.01). AmB treatment also enhanced INF-γ,
TNF-α, and IL-2 levels and declined secretion of IL-10
and IL-4 (Figure 12).
Bioactive fractions were devoid of any toxic effects on
liver and kidney
To assess the adverse toxicity of ALE and ASE, the frac-
tions were administered in normal mice at 200 mg/kg bw
and 2 weeks post treatment, sera from different groups
were analyzed to assess the liver and kidney functions.
No significant alterations in liver enzymes ALP, SGPT
and SGOT were visible in ALE and ASE treated groups.Kidney function was also not impaired as indicated by
normal range of serum urea and creatinine (Figure 13).
Discussion
As proclaimed, plant derived secondary metabolites have
become a focal point for discovery of antileishmanials with
leishmanicidal and immunomodulatory properties. Previ-
ous studies which have divulged that leishmanicidal plants
and plant secondary metabolites can potentiate key cel-
lular immune responses, have proven to be coherent in
the quest for more efficacious and less toxic antileish-
manial drugs [4,27,28]. On guided lines, we evaluated
the antileishmanial and immunostimulatory potential of
A. indica. Major findings, from the present work under-
taken were that ethanolic fractions of A. indica leaves
(ALE) and seeds (ASE) inhibited the growth of L. donovani
promastigotes via induction of apoptosis and provided pro-
tection to BALB/c mice against L. donovani infection via
Figure 9 Analysis of T-cell proliferation in splenocytes. Splenocytes from respective experimental groups were re-stimulated with SLA and
assessed for lymphoproliferation as described in Methods. Inset shows respective percentages of CFSE-positive cells.
Figure 10 CD4+ and CD8+ upregulation induced by bioactive fractions. Splenic T lymphocytes from different treatment groups were
co-stained with PE-conjugated antimouse-CD4 and FITC conjugated antimouse-CD8 antibodies. Results are expressed as dot plots and are
representative of one of the two independent experiments performed. Inset shows percentages of CD4+ T cells (lower right) and CD8+ T cells
(upper left) in respective quadrants.
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Figure 11 Analysis of CD80 and CD86 expression on macrophages. Peritoneal macrophages from naïve, infected and variously treated mice
were dual-stained with antimouse-CD80-APC and antimouse-CD86-PeCy7. Bar graphs depict changes in (a) CD80 and (b) CD86 expression in the
different groups. ***P < 0.001, **P < 0.01, *P < 0.05 and ns- not significant with respect to infection control.
Figure 12 Bioactive fractions altered cytokine expression profile in L. donovani infected mice. Th1/Th2 cytokine levels were determined in
SLA stimulated culture supernatants of spleen cells by cytokine bead array. ***P < 0.001, **P < 0.01 and *P < 0.005 with respect to infection control.
# represents P < 0.001, statistical significance of INF with respect to normal group.
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Figure 13 Estimation of in vivo side effects of bioactive fractions. ALE and ASE treated normal mice were bled and sera from the different
experimental groups was used to estimate liver enzymes and kidney metabolites as described in Methods.
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any potential toxicity.
ALE and ASE repressed the growth of L. donovani
promastigotes in a time- and dose-dependent manner,
induced morphological alterations and their mode of
induced cell death was cytocidal. A. indica extracts have
been previously reported for their antileishmanial prop-
erties against L. amazonensis [10], L. major [8,9], and
L. donovani clinical isolates and Dd8 strain [13]. We ob-
served significant leishmanicidal activity of A. indica
leaves and seeds ethanolic fractions on the L. donovani
promastigotes (AG83), which have not been reported
earlier. On the other hand, Sharma et al., [29] reported
that methanolic extracts of A. indica leaves and stem
bark were not active against L. donovani KE16. Suchcontrasting results may be accounted for differential
virulence of the leishmanial strains (AG83 vs Dd8 vs
KE16), difference in methods of extract preparation and
also due to distinct profiles of secondary metabolites in
these plant parts which varies in different geographic re-
gions [30] including plants in the same country [31].
The leishmanicidal efficacy of A. indica fractions was
found independent of quercetin, which has previously
been reported to be antileishmanial ([32] and references
therein). Quercetin was not included as a bioactive
standard in any of the studies as it was not detected in
the bioactive fractions by GC-MS analysis and this was
also confirmed by thin layer chromatography (data not
shown). However, isolation of quercetin [33] and of
quercetin glycosides [34] has been done from aqueous
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cetin in ALE may be due to different extraction proce-
dures. Other major constituents of ALE and ASE were
identified by GC-MS analysis. The major constituent
present in ALE was 1,2-Benzenedicarboxylic acid (25.21%)
and was also detected in seed fraction (7.14%). This is a
known component of Ceratonia siliqua essential oil,
which exhibited antibacterial, antifungal and antitumor
properties as well as of another medicinal plant, Cleome
burmanni [35,36]. Stigmasterol acetate (16.95%), Ergos-
terol acetate (7.47%), stigmasterol (4.74%) along with
γ-Sitosterol (1.3%) were detected in ALE. Both stigmas-
terol and γ-Sitosterol are endowed with anticancer, anti-
microbial, antifungal, and antimycobacterial properties
[37-40]. Stigmasterol and Ergosterol acetate are reported
to be antileishmanial against L. infantum [41]. In ALE,
palmitic acid (7.90%) was detected whereas linoleic acid
(7.40%) and palmitic acid (6.84%) were identified in ASE.
Both unsaturated [42] as well as saturated fatty acids have
been shown to exhibit leishmanicidal activity and palmitic
acid has been reported to be antileishmanial by Cunningham
et al., [43]. Phytol (3.97%) and retinol (2.59%) were
also detected in ALE. While, phytol presents a diverse
spectrum of biological activities [44-46] and was also pre-
viously detected in antitrypanosomal extract of Strychnos
spinosa [47] and antileishmanial extracts of Arrabidaea
chica [48], Retinol (vitamin A alcohol) is endowed with
antiplasmodial activity [49]. Another major component
in ALE cis, cis, cis-7, 10, 13-Hexadecatrienal (5.90%)
has been previously also detected in methanolic extract
of A. indica leaves and was found to be larivicidal
against Aedes aegypti [50]. Major components identified
in ASE were not reported earlier for their biological ac-
tivities, however, 9-Octadecenoic acid methyl ester
(5.59%) and Ethylpalmitate (3.61%) have been related to
antimicrobial properties [51,52].
Leishmania species are well known to exhibit apoptosis
like changes in response to a diverse range of stimuli in-
cluding plant extracts [16,18]. ALE and ASE treatment
also triggered apoptosis like changes in L. donovani pro-
mastigotes characterized by PS externalization, induction
of DNA fragmentation, cell cycle arrest at sub-G0/G1
phase, mitochondrial membrane depolarization and ROS
generation. As discussed earlier, the anti-promastigote ac-
tivity of A. indica is reported against different Leishmania
species, but none of the studies have elucidated the mech-
anism of action of the bioactive extracts. A. indica extracts
are known to stimulate apoptosis in many cancer cell lines
[53,54] and in conformity, our results elucidate that A.
indica bioactive fractions induce apoptosis mediated cell
death in Leishmania promastigotes.
The anti-amastigote efficacy of the bioactive fractions
was evaluated in a macrophage-amastigote model. The
ALE and ASE reduced intra-macrophagic parasite growthof L. donovani. Aqueous extracts of A. indica have been
demonstrated to potently inhibit axenic amastigote
growth of L. donovani (Dd8 and other isolates) [13]. A.
indica leaves ethanolic extract and dichloromethane frac-
tion of nut tegument profoundly contained the growth of
L. amazonensis amastigotes [10]. In accordance, our data
also elaborated effectualness of A. indica bioactive frac-
tions against L. donovani amastigotes. Selectivity index
value was determined to assess cytotoxicity of the test
fractions against mammalian macrophages. SI values
above 10 were considered specific as described in case
of other antiprotozoal compounds including those for
Leishmania [55,56]. ALE possessed high selectivity as
demonstrated by SI of 26.10 and ASE was not found to
be toxic at all. This is in agreement with earlier studies
where A. indica extracts were revealed to be marginally
toxic against peritoneal macrophages [10] and human
peripheral blood mononuclear cells [13].
ALE and ASE (200 mg/ kg bw) cured BALB/c mice of
L. donovani infection with only marginal levels of para-
sites persisting in the liver and spleen along with restor-
ation of liver and spleen weights to normal range. Partial
resolution of infection was evident at lower doses of the
bioactive fractions and changes in liver and spleen
weight were less significant. A. indica methanolic extract
successfully cured lesions in cutaneous leishmaniasis pa-
tients [11] and an aqueous extract of A. indica whole
plant was demonstrated to reduce L. donovani Dd8 bur-
den in BALB/c mice [12]. It is well established with VL
that even a successful chemotherapy cannot completely
eradicate all the parasites from infection sites; despite
that patients with intact T cells display normal charac-
teristics of clinical cure long after recovery [57,58]. Cure
of infection in VL and presence of residual parasites has
been divulged by others also [27,28]. The resolution of
VL infection was accompanied by polarization of im-
mune response towards Th1 type as evident from DTH,
lymphoproliferative response, increased CD4+ and CD8+
T cell numbers and upregulation of serum IgG2a levels.
Further, bioactive fractions enhanced NO production as
well as elevated CD80/CD86 expression in macrophages.
A. indica has been reported to possess immunomodula-
tory and adjuvant properties [59-61]. Our results were in
accordance with these and study of different facets of
CMI reinstated that potent immunomodulatory efficacy
of A. indica fractions may be a major contributory factor
in its leishmanicidal activity. AmB used as a positive
control in this study, is known to be leishmanicidal by
direct activity independent of host immune activation
[62] as well as by exerting immune modulation where it
has been demonstrated to induce DTH, enhance T cell
proliferation, modulate serum IgG isotype levels, and in-
duce NO production to skew the immune response to-
wards Th1 type [23].
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rophages via secretion of Th1 cytokines. In human VL,
DTH also holds significance in the fact that perceptible
clinical cure in the absence of a positive DTH response
is often associated with relapse in infection [63]. Our
data indicates that ALE and ASE (200 mg/kg bw) in-
duced notable DTH response. Dominance of humoral
response and depression of CMI is noteworthy during
progressive VL. Serum levels of IgG2a and IgG1 indir-
ectly affirm the activation of Th1 and Th2 cells, respect-
ively. ALE and ASE (200 mg/kg bw) decreased the IgG1
levels and elevated IgG2a levels significantly which pred-
icates the Th1 stimulating potential of the bioactive frac-
tions. Further, the bioactive fractions treatment resulted
in upregulation of NO production, which validated that
parasite clearance was mediated via NO generation, the
major microbicidal molecule responsible for intracellular
killing of Leishmania parasites [27]. Restoration of an ef-
fective Th1 immune response was also investigated by
assessing lymphoproliferation. Treatment with ALE and
ASE annihilated T cell anergy evidenced in infected
state, and a conspicuous T cell proliferation was appar-
ent in all treated groups including AmB. Increase in T
lymphocyte subpopulations (CD4+ and CD8+) after
treatment with ALE and ASE also ascertained the im-
munomodulatory potency of the bioactive fractions.
CD4+ T lymphocytes are already known to head VL re-
covery [64] but lately CD8+ T lymphocytes have been
designated as equally important. During the course of
VL infection, L. donovani suppresses the expansion and
effector functions of CD8+ T cells [65]. CD8+ T cells
have been shown to aid parasite clearance in vivo in
BALB/c mice by direct lysis of infected cells as well as
by recognizing L. donovani derived peptides from APCs
[66]. Our bioactive fractions treatment led to the expan-
sion of CD4+ T cells and restoration of CD8+ T cells to
normal range.
CD80 and CD86 co-stimulatory molecules on APCs
provide a vital link via interacting with CD28 on T cells
that fortifies the interaction between T cell receptor and
MHC. CD80-CD86 expression, which was muted during
infection, was retrieved by treatment with ALE and ASE.
Similar recovery of CD80-CD86 expression has been re-
ported earlier in case of miltefosine [67] and pyrazina-
mide [68] treatment. In VL during disease progression,
cytokine expression profile is skewed towards Th2 type,
and successful restoration of immunity is reflected by in-
duction of pro-inflammatory cytokines and polarization
of immune response towards Th1 bias. The resolution of
disease upon bioactive fractions treatment was accom-
panied by elevation in INF-γ, TNF-α and IL-2. INF-γ is
potent macrophage activator, which promotes the class
switching in B cells to produce IgG2a. Also, INF-γ in
synergy with TNF-α, induces NOS II to produce NO themajor microbicidal molecule against Leishmania and di-
rects the immune response towards Th1 in the presence
of IL-2 [69]. The induction of Th1 cytokines was accom-
panied by decline in levels of IL-4 and IL-10. ALE and
ASE treatment reduced the levels of IL-4, which is re-
sponsible for production of IgG1 thus promoting Th2
phenotype. Our results also divulged elevated IgG2a
serum levels in bioactive fractions treated group in com-
parison to IgG1, which can be well correlated to the en-
hanced IFN-γ production and down modulation of IL-4
secretion. Further, our A. indica bioactive fractions down
regulated IL-10 production, a cytokine most closely re-
lated to disease exacerbation. Despite the ample produc-
tion of IFN-γ in both murine and human VL, the
infected hosts are usually handicapped in controlling
the progressive disease, and the host inefficiency is
attributed to high levels of IL-10 [4]. IL-10 impairs
accessory cell functions including down-regulation of
CD80 and CD86 expression leading to limited secretion
of pro-inflammatory cytokines and suppression of NO
production [70]. Our bioactive fractions up-regulated
CD80-CD86 expression and NO production, which may
be due to significant decline in IL-10 and elevation in
INF-γ, and TNF-α level.
In vivo toxicity of the bioactive fractions was assessed
at higher dose (200 mg/kg bw) in naïve mice. None of
the treatment groups significantly altered serum
SGOT, SGPT, ALP and urea as well as creatinine levels
indicating that A. indica bioactive fractions were nei-
ther renal nor hepatotoxic. Non-toxic nature of A.
indica has been illustrated in previous studies where
the leaf preparations did not alter the serum ALP,
SGOT and SGPT as well as urea and creatinine levels
and no histological alterations were observed in liver
and kidney sections of Swiss albino mice [71]. This was
also supported by others [72,73] who reported that
A. indica leaves and seeds were indeed hepato- and
nephro-protective and their treatment did not alter liver
and kidney functions.
Taken together, our data elaborates the antileishmanial
efficacy of A. indica leaves and seeds ethanolic fractions,
which is apparently potentiated by their immunostimula-
tory capacity.
Conclusion
A. indica has been an integral part of Indian traditional
medicine with each part of the plant endowed with mis-
cellaneous medicinal properties. Here in, we demonstrated
the potent leishmanicidal and immunomodulatory efficacy
of A. indica leaves and seeds fractions, which advocates
further standardization of these bioactive fractions for ex-
ploration as complementary medicine in the management
of leishmaniasis either individually or more likely as a part
of combination therapy.
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